Servier agreed to acquire Day One Biopharmaceuticals for about $2.5 billion, adding the FDA‑approved pediatric glioma drug Ojemda and an early-to-late stage oncology pipeline to its portfolio. The deal, announced March 6, transfers a commercial-stage asset that recorded roughly $155 million in 2025 sales and several development programs for pediatric and adult solid tumors. Servier framed the acquisition as a strategic fit with its existing glioma franchise, including Voranigo, and says it will fund the purchase from cash and investments. The cash offer represented a roughly 68% premium to Day One’s closing price and is expected to close in Q2 pending customary approvals. Servier’s U.S. leadership emphasized the company’s intent to scale rare‑cancer capabilities, linking the transaction to broader ambitions in targeted oncology and the development of therapies for high‑unmet‑need populations. The deal also gives Servier immediate commercial presence in a niche pediatric oncology segment while adding R&D programs that could feed future registrational trials.